Silo Pharma is Developing a Ketamine Implant for Pain Management

Silo Pharma is Developing a Ketamine Implant for Pain Management

Silo Pharma, a developmental-stage biopharmaceutical company, has entered into a joint development agreement with Kymanox to advance SP-26, a ketamine-loaded implant device aimed at managing chronic pain and fibromyalgia.

New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here

Advancing Pain Management

The collaboration focuses on creating a subcutaneous insertion device for SP-26, designed to deliver controlled, time-released doses of ketamine. Kymanox will lead the proof-of-concept design and prototype development to determine the optimal tissue insertion depth. Silo Pharma’s CEO, Eric Weisblum, emphasized the importance of this partnership in progressing SP-26 into preclinical studies.

Here’s a breakdown of how the SP-26 implant works, its benefits compared to current options, and its potential implications for treatment:

AspectDetails
How the Implant Works– Subcutaneous device loaded with ketamine.
– Delivers controlled, time-released doses into the tissue.
– Inserted at an optimal depth determined by prototype testing.
Benefits Compared to Current OptionsConvenience: Potential for at-home use versus in-clinic infusions or injections.
Consistency: Provides steady drug release over time, avoiding peaks and troughs in drug levels.
Minimally Invasive: Reduces the need for frequent hospital or clinic visits.
Reduced Dependence: May decrease reliance on traditional pain medications, such as opioids.
Potential Implications for TreatmentChronic Pain: Offers a new, sustained relief option for conditions like fibromyalgia.
Accessibility: Makes advanced pain management available to more patients outside clinical settings.
Innovation: Could pave the way for more implantable devices in other therapeutic areas.

Ketamine Implant: Potential At-Home Treatment

Preclinical research aims to align SP-26’s safety profile with FDA standards for potential at-home use. If approved, SP-26 could become the first at-home injectable ketamine-based therapy, offering a new avenue for patients seeking convenient pain management solutions.

Silo Pharma’s Broader Initiatives

Beyond SP-26, Silo Pharma is developing SPC-15, an intranasal treatment targeting PTSD and stress-induced anxiety disorders. The company is also exploring treatments for Alzheimer’s disease and multiple sclerosis, reflecting its commitment to addressing various central nervous system conditions.

Implications for Chronic Pain Treatment

The development of SP-26 represents a significant advancement in chronic pain management. By potentially providing sustained relief through a minimally invasive implant, it could reduce reliance on traditional pain medications and improve patients’ quality of life.

As Silo Pharma and Kymanox move forward with this collaboration, the medical community and patients alike will be watching closely. Could SP-26 redefine the landscape of chronic pain treatment? The outcomes of this partnership may offer new hope for those seeking effective and convenient pain management options.

Healing Maps Editorial Staff

Healing Maps Editorial Staff

View all posts by Healing Maps Editorial Staff

The Healing Maps Editorial Team has decades of experience across all facets of the psychedelic industry. From assessing studies and clinic research, to working with clinician's and clinics, we help provide data-backed information to psychedelic-curious individuals across the globe.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Explore Psychedelic Therapy Regions